Literature DB >> 34052327

Androgens in prostate cancer: A tale that never ends.

Zemin Hou1, Shengsong Huang2, Zhenfei Li3.   

Abstract

Androgens play an essential role in prostate cancer. Clinical treatments that target steroidogenesis and the androgen receptor (AR) successfully postpone disease progression. Abiraterone and enzalutamide, the next-generation androgen receptor pathway inhibitors (ARPI), emphasize the function of the androgen-AR axis even in castration-resistant prostate cancer (CRPC). However, with the increased incidence in neuroendocrine prostate cancer (NEPC) showing resistance to ARPI, the importance of androgen-AR axis in further disease management remains elusive. Herein we review the steroidogenic pathways associated with different disease stages and discuss the potential targets for disease management after manifesting resistance to abiraterone and enzalutamide.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Abiraterone resistance; Androgen receptor; Bipolar androgen therapy; Enzalutamide resistance; Steroidogenesis

Mesh：

Substances：

Year:  2021        PMID： 34052327     DOI： 10.1016/j.canlet.2021.04.010

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  8 in total

1.  Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors.

Authors:  Qilong Tan; Ziqun Liu; Xiaobo Gao; Yibo Wang; Xuefeng Qiu; Jiahui Chen; Liuchun Liang; Hongqian Guo; Shengsong Huang; Denglong Wu; Bing Zhou; Ronggui Hu; Zhenfei Li
Journal:  Oncogene       Date:  2022-09-16       Impact factor: 8.756

2.  Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment.

Authors:  Zejie Mei; Tao Yang; Ying Liu; Yuanyuan Gao; Zemin Hou; Qian Zhuang; Dongyin He; Xuebin Zhang; Qilong Tan; Xuyou Zhu; Yingyi Qin; Xi Chen; Chengdang Xu; Cuidong Bian; Xinan Wang; Chenyang Wang; Denglong Wu; Shengsong Huang; Zhenfei Li
Journal:  Cell Rep Med       Date:  2022-04-20

3.  An Extensive Pharmacological Evaluation of New Anti-Cancer Triterpenoid (Nummularic Acid) from Ipomoea batatas through In Vitro, In Silico, and In Vivo Studies.

Authors:  Muhammad Majid; Anam Farhan; Muhammad Imran Asad; Muhammad Rashid Khan; Syed Shams Ul Hassan; Ihsan-Ul Haq; Simona Bungau
Journal:  Molecules       Date:  2022-04-12       Impact factor: 4.927

4.  Systematic Elucidation of the Aneuploidy Landscape and Identification of Aneuploidy Driver Genes in Prostate Cancer.

Authors:  Yun Peng; Yuxuan Song; Haitao Wang
Journal:  Front Cell Dev Biol       Date:  2022-01-21

5.  Inhibiting 3βHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer.

Authors:  Zemin Hou; Shengsong Huang; Zejie Mei; Longlong Chen; Jiacheng Guo; Yuanyuan Gao; Qian Zhuang; Xuebin Zhang; Qilong Tan; Tao Yang; Ying Liu; Yongnan Chi; Lifengrong Qi; Ting Jiang; Xuefeng Shao; Yan Wu; Xiaojun Xu; Jun Qin; Ruobing Ren; Huiru Tang; Denglong Wu; Zhenfei Li
Journal:  Cell Rep Med       Date:  2022-03-15

6.  A novel prognostic model based on three clinic-related miRNAs for prostate cancer.

Authors:  Ping Che; Shihao Jiang; Weiyang Zhang; Huixuan Zhu; Daorong Hu; Delin Wang
Journal:  Front Surg       Date:  2022-07-25

7.  The clinical efficacy and limitations of dutasteride-regulated abiraterone metabolism in abiraterone-resistant patients: a prospective single-arm clinical trial in Chinese patients.

Authors:  Ying Liu; Tao Yang; Chengdang Xu; Xi Chen; Yongnan Chi; Weidong Zhou; Wei Le; Cuidong Bian; Zhenfei Li; Shengsong Huang; Denglong Wu
Journal:  Transl Androl Urol       Date:  2022-08

8.  Citric Acid as a Potential Prostate Cancer Biomarker Determined in Various Biological Samples.

Authors:  Magdalena Buszewska-Forajta; Fernanda Monedeiro; Adrian Gołębiowski; Przemysław Adamczyk; Bogusław Buszewski
Journal:  Metabolites       Date:  2022-03-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.